(571) 447-5500

FDA Tobacco Registration and Product Listing Requirements for Foreign Manufacturers

FDA has proposed new registration and product listing requirements for foreign tobacco manufacturers supplying products to the U.S. market. EAS Consulting Group can help organizations evaluate potential impacts, prepare for future compliance obligations, and navigate FDA regulatory requirements.

FDA Proposes Registration and Product Listing Requirements for Foreign Tobacco Manufacturers

On June 29, 2026, FDA published a proposed rule entitled Establishment Registration and Product Listing for Tobacco Products. If finalized, the rule would require foreign tobacco product manufacturers to register their facilities with FDA and submit detailed product listing information before products can be imported into the United States.

The proposal is intended to provide FDA with greater visibility into the global tobacco supply chain while strengthening oversight of imported tobacco products, including electronic nicotine delivery systems (ENDS), e-cigarettes, nicotine products, and other tobacco products entering the U.S. market.

The proposed rule would also expand the scope of organizations that may be considered manufacturers under FDA regulations, potentially impacting specification developers, contract manufacturers, repackagers, relabelers, and other supply chain partners.

Who May Be Impacted?

Foreign Tobacco Manufacturers

Companies that manufacture tobacco products intended for import into the United States.

Specification Developers

Organizations that design or control product specifications, even when manufacturing activities are outsourced.

Repackagers and Relabelers

Companies involved in modifying packaging, labeling, or distribution configurations.

ENDS and E-Cigarette Manufacturers

Manufacturers of electronic nicotine delivery systems, e-liquids, disposable vaping products, cartridges, pods, and related components.

Contract Manufacturers

Third-party manufacturers producing tobacco products on behalf of another company.

Importers and U.S. Distributors

Organizations responsible for importing or distributing tobacco products within the United States.

Key Requirements Included in FDA’s Proposed Rule

Facility Registration

Foreign establishments engaged in the manufacture, preparation, compounding, or processing of tobacco products would be required to register with FDA before products are imported into the United States.

Product Listing

Manufacturers would be required to provide detailed information for each tobacco product, including product identification, packaging details, nicotine information, and other required attributes.

FDA Inspection Authority

Foreign facilities subject to registration requirements may become subject to FDA inspection.

Electronic Submissions

FDA proposes electronic registration and product listing submissions through its online systems, with limited exceptions.

Recordkeeping Requirements

Manufacturers would be required to maintain product labeling, advertising, and consumer information records for specified periods.

Ongoing Updates

The proposal includes annual registration requirements and periodic product listing updates.

Questions Companies Should Be Asking Now

  • Will our facilities be subject to FDA registration requirements?
  • Are we considered a manufacturer under the proposed rule?
  • Which products would require listing with FDA?
  • Do we have the information necessary to complete product listings?
  • Are we prepared for potential FDA inspections?
  • How could the rule impact our supply chain and import activities?
  • Should our company submit comments to FDA before the public comment deadline?

While FDA continues to evaluate public comments, organizations can begin assessing how the proposal may affect their operations and regulatory responsibilities.

How EAS Consulting Group Can Help

Regulatory Impact Assessments

Evaluate how FDA’s proposed requirements may apply to your organization, facilities, products, and supply chain.

Product Listing Strategy

Identify required product information and develop a plan for future listing submissions.

FDA Inspection Readiness

Assess facility readiness and prepare for potential FDA inspections.

Regulatory Gap Assessments

Review existing procedures, documentation, and recordkeeping practices against proposed requirements.

Comment Development Support

Assist organizations in evaluating the proposal and preparing comments for FDA consideration.

Tobacco Regulatory Consulting

Provide strategic guidance on FDA tobacco regulations, submissions, compliance programs, and enforcement matters.

Why Choose EAS Consulting Group

For more than 25 years, EAS Consulting Group has helped regulated industries navigate complex FDA requirements. Our tobacco regulatory experts assist manufacturers, importers, distributors, and supply chain partners with regulatory strategy, compliance, submissions, inspections, and enforcement-related matters.

Our team understands both the operational and regulatory challenges facing companies participating in the global tobacco supply chain and can help organizations evaluate the potential impact of FDA’s proposed registration and product listing requirements.

Frequently Asked Questions

What is FDA's proposed tobacco registration and product listing rule?

On June 29, 2026, FDA published a proposed rule titled Establishment Registration and Product Listing for Tobacco Products. The proposal would establish formal registration and product listing requirements for both domestic and foreign tobacco product manufacturers and provide detailed procedures for submitting information to FDA.

The proposed rule is intended to improve FDA’s visibility into the tobacco product supply chain, support enforcement efforts against unauthorized products, and help identify manufacturers and products entering the U.S. market. FDA is accepting public comments on the proposal before determining whether to issue a final rule.

Who must register under FDA's proposed tobacco rule?

If finalized, the proposed rule would require owners and operators of establishments engaged in the manufacture, preparation, compounding, or processing of tobacco products intended for commercial distribution in the United States to register with FDA.

The proposal would apply to both domestic and foreign establishments and may affect a broader range of organizations than some companies expect, including certain specification developers, contract manufacturers, repackagers, and relabelers.

Does the proposed rule apply to foreign manufacturers?

Yes. One of the primary purposes of the proposed rule is to extend registration and product listing requirements to foreign tobacco product manufacturers that supply products to the U.S. market.

FDA has stated that the proposal is intended to close a longstanding regulatory gap by providing greater visibility into foreign facilities and products entering the United States. Foreign manufacturers would generally be required to register before products manufactured at their facilities are imported or offered for import into the United States.

Will FDA inspect foreign tobacco manufacturing facilities?

If finalized, the proposed rule would subject registered foreign tobacco manufacturing facilities to FDA inspection authority.

Companies should begin evaluating whether their facilities, documentation systems, and quality processes are prepared to support a potential FDA inspection. Inspection readiness may become an increasingly important consideration for organizations manufacturing products intended for distribution in the United States.

Are e-cigarette and ENDS manufacturers included?
Yes. FDA has indicated that the proposal would apply to tobacco products subject to the agency’s tobacco regulatory authority, including electronic nicotine delivery systems (ENDS) and e-cigarette products.

Manufacturers of e-liquids, disposable vaping products, cartridges, pods, and related products should carefully review the proposal to determine how registration, product listing, and recordkeeping requirements may apply to their operations.

What information is required in a tobacco product listing?
Under the proposed rule, manufacturers would be required to submit identifying information for each tobacco product manufactured for commercial distribution.

Depending on the product type, required information may include brand and subbrand names, product category and subcategory, package details, characterizing flavors, nicotine source, nicotine concentration, and other product-specific information. Certain ENDS products may require additional information such as e-liquid volume, battery capacity, and wattage.

What is a specification developer?
A specification developer is generally an organization that designs, develops, owns, or controls a product’s specifications, even when manufacturing activities are performed by another company.

FDA’s proposed rule specifically addresses specification developers and may treat some of these entities as manufacturers for registration and product listing purposes. Companies that outsource production but maintain control over product design or specifications should carefully evaluate how the proposal may affect their responsibilities.

Does the proposal affect contract manufacturers?
Potentially. FDA’s proposed definition of manufacturer includes certain entities involved in manufacturing tobacco products on behalf of another company.

Contract manufacturing arrangements can be complex, and responsibilities may vary depending on the relationship between the parties involved. Companies utilizing third-party manufacturing should review the proposal carefully to understand how registration, product listing, and recordkeeping obligations may apply.

When would foreign manufacturers need to register?
Under the proposal, foreign manufacturers would generally be required to register before any tobacco product manufactured at their establishment is imported or offered for import into the United States.

FDA is currently accepting comments on the proposed requirements. Registration timelines and implementation details may change before a final rule is issued.

When does the FDA comment period close?

FDA is currently accepting public comments on the proposed rule through September 14, 2026.

Manufacturers, importers, distributors, industry associations, and other stakeholders may submit comments to FDA regarding the proposal, its potential impacts, and implementation considerations before the agency determines whether to issue a final rule.

Can EAS help prepare comments to FDA?

Yes. EAS Consulting Group assists companies in evaluating proposed FDA regulations and understanding how new requirements may affect their products, facilities, operations, and supply chains.

Our tobacco regulatory experts can help organizations review proposed requirements, identify potential business impacts, develop regulatory strategies, and prepare well-supported comments for FDA consideration during the public comment period.

Related News

Transition from Computer System Validation (CSV) to Computer Software Assurance (CSA)

The life science industries, including pharmaceutical, medical device, biotechnology, biological, and tobacco and tobacco-related products continue to embrace new technology to improve delivery of quality products in compliance with FDA. In addition, we’ve seen a trend toward making use of cloud services, Software-as-a-Service (SaaS) solutions, and other technical innovations such as use of Artificial Intelligence (AI), Machine Learning (ML) and Large Language Models (LLMs), such as ChatGPT that have more recently begun to be used more heavily in life science companies.

21 CFR Part 11 (Electronic Records & Signatures) Compliance for Computer Systems Regulated by FDA

The Webinar will focus on the importance of ensuring that electronic record/electronic signature (ER/ES) capability built into FDA-regulated, or “GxP” computer systems meets compliance with 21 CFR Part 11. This includes development of a company philosophy and approach, and incorporating it into the overall computer system validation program and plans for individual systems that have this capability.
FDA’s 21 CFR Part 11 was enacted in 1997 and implementation success across the pharmaceutical and other regulated industries has been mixed. There are very specific limitations that arise when using ER/ES capability, such as the elimination of print capability to prevent users from making decisions based on a paper record as opposed to the electronic, or system of record.

Validation & Use of FDA-Regulated Systems Using AI, ML & Large Language Models (LLMs), such as ChatGPT

The life science industries, including pharmaceutical, medical device, biotechnology, biological, and tobacco and tobacco-related products continue to embrace new technology to improve delivery of quality products in compliance with FDA. In addition, we’ve seen some trends toward making use of cloud services, Software-as-a-Service (SaaS) solutions, and other technical innovations that have more recently begun to be used more heavily in life science companies.
Artificial Intelligence (AI), Machine Learning (ML) and Large Language Models (LLMs), such as ChatGPT are beginning to find a presence at these companies. While life science companies tend to lag behind other markets in using these technologies, they are catching up and we are seeing much more activity related to AI use in software applications used to develop, produce, test, and manage life science products with quality and compliance.
As the pace of technological innovation and evolution becomes more intense, there is a critical need for computer system validation, 21 CFR Part 11 (Electronic Records and Electronic Signatures) compliance, and data integrity assurance to continue in environments where artificial intelligence (AI) and machine learning (ML) are becoming prevalent.
FDA became alarmed by the lack of compliance to meet data integrity and Part 11 requirements during the last decade. Out of compliance citations during this period, including Form 483s and Warning Letters have skyrocketed for these key areas of compliance. But why?
Based on discussions with clients and stakeholders at conferences and meetings, it has become more and more obvious that most of the performers in industry are under management pressure to do more work with fewer resources and in less time. This continues to lead performers to seek faster and easier ways to get the work done, and opens the door to more conversation around the use of AI/ML in software development, testing, and support.

Data Integrity and Governance for Computer Systems Regulated by FDA

During this webinar, we will focus on the importance of ensuring that both structured (e.g., database records) and unstructured (e.g., Word document, PDF, spreadsheet) data are maintained with integrity through their chronological life cycle. This requires recognition that FDA is laser-focused on data integrity issues based on industry inspection trends during the past decade.
FDA’s Guidance for Data Integrity, issued in December 2018, did not include a single new requirement. Instead, it reiterated parts of the Code of Federal Regulations (CFRs) that have been in place for decades, and which industry was failing to meet.

Emerging FDA Trends in Computer System Validation (CSV)

The life science industries, including pharmaceutical, medical device, biotechnology, biological, tobacco and tobacco-related products continue to embrace new technology to improve delivery of quality products in compliance with FDA.
We have seen the recent trend in industry toward using cloud-based services, Software-as-a-Service (SaaS) solutions, and other technical innovations. More recently, we have begun to see newer, emerging technologies including Artificial Intelligence (AI), Machine Learning (ML) algorithms & Large Language Models (LLMs), such as ChatGPT begin to find a presence within these companies.
While life science companies tend to lag behind other markets in using these technologies, they are catching up and we are seeing much greater use of AI in the development, testing, release & management of life science products with quality and compliance. This is most predominant in the medical device industry, where we find both medical devices that include software as a product component & Software-as-a-Medical-Device (SaMD) products that function as a medical device without the need for any hardware.

Questions About FDA’s Proposed Tobacco Registration Rule?

EAS Consulting Group’s tobacco regulatory experts can help you evaluate the proposal, understand potential impacts, and prepare for future requirements.

Need Regulatory Support?

Start the Conversation Today

Subscribe to the EASeNews Newsletter: